 | • レポートコード：MRC2305D104 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、252ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に982.38百万ドルであった世界の前立腺がん診断市場規模が、2022年に1,119.12百万ドルに成長し、更に年平均14.09％拡大して2027年までに2,167.25百万ドルに達すると予測しています。当市場調査レポートでは、前立腺がん診断の世界市場を多角的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、検査種類別（確認検査、予備検査）分析、年齢層別（55～75歳、55歳以下、75歳以上）分析、エンドユーザー別（がん研究所、病院附属検査室、独立診断研究所）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容を掲載しています。また、当書内の企業情報には、Abbott Laboratories、Accuquik Test Kits、ACON Laboratories, Inc.、Astellas Pharma Inc.、AstraZeneca PLC、Bayer AG、Beckman Coulter Inc.、BioMérieux SA、Dendreon Pharmaceuticals LLC、DiaSorin S.p.A.、Eurolyser Diagnostica GmbH、Exact Sciences Corp.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の前立腺がん診断市場規模：検査種類別 - 確認検査の市場規模 - 予備検査の市場規模 ・世界の前立腺がん診断市場規模：年齢層別 - 前立腺がん診断（55～75歳）の市場規模 - 前立腺がん診断（55歳以下）の市場規模 - 前立腺がん診断（75歳以上）の市場規模 ・世界の前立腺がん診断市場規模：エンドユーザー別 - がん研究所における市場規模 - 病院附属検査室における市場規模 - 独立診断研究所における市場規模 ・世界の前立腺がん診断市場規模：地域別 - 南北アメリカの前立腺がん診断市場規模 アメリカの前立腺がん診断市場規模 カナダの前立腺がん診断市場規模 ブラジルの前立腺がん診断市場規模 ... - アジア太平洋の前立腺がん診断市場規模 日本の前立腺がん診断市場規模 中国の前立腺がん診断市場規模 インドの前立腺がん診断市場規模 韓国の前立腺がん診断市場規模 台湾の前立腺がん診断市場規模 ... - ヨーロッパ/中東/アフリカの前立腺がん診断市場規模 イギリスの前立腺がん診断市場規模 ドイツの前立腺がん診断市場規模 フランスの前立腺がん診断市場規模 ロシアの前立腺がん診断市場規模 ... - その他地域の前立腺がん診断市場規模 ・競争状況 ・企業情報 |
The Global Prostate Cancer Diagnostics Market size was estimated at USD 982.38 million in 2021 and expected to reach USD 1,119.12 million in 2022, and is projected to grow at a CAGR 14.09% to reach USD 2,167.25 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Prostate Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Test Type, the market was studied across Confirmatory Tests and Preliminary Tests. The Confirmatory Tests is further studied across Biopsy, PCA3 Tests, and Trans-rectal Ultrasound.
Based on Age Group, the market was studied across Age 55-75, Age <55, and Age>75.
Based on End-User, the market was studied across Cancer Research Institutes, Hospital Associated Laboratories, and Independent Diagnostic Laboratories.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Prostate Cancer Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Prostate Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Prostate Cancer Diagnostics Market, including Abbott Laboratories, Accuquik Test Kits, ACON Laboratories, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter Inc., BioMérieux SA, Dendreon Pharmaceuticals LLC, DiaSorin S.p.A., Eurolyser Diagnostica GmbH, Exact Sciences Corp., F. Hoffmann-La Roche AG, Fujirebio, Hologic Inc, Humasis Co, Ipsen SA, Koninklijke Philips NV, Life Length, MDxHealth, Metamark Genetics, Inc, Myriad Genetics, Inc., OPKO Health, Inc., Prostatype Genomics, Proteomedix AG, Sanofi S.A., Siemens Healthineers AG, Telo Genomics Corp., and Tolmar Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Prostate Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Prostate Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Prostate Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Prostate Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Prostate Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Prostate Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Prostate Cancer Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising aging population and increasing prevalence rate of prostate cancer
5.1.1.2. Growing government’s initiatives for advancement in technology in diagnosis and creating awareness regarding cancer
5.1.2. Restraints
5.1.2.1. Stringent regulations and high cost of diagnosis
5.1.3. Opportunities
5.1.3.1. Innovation in drugs and developments in genomics and proteomics
5.1.3.2. Imaging research and advancements for accurate detection of prostate cancer
5.1.4. Challenges
5.1.4.1. Low success rate of clinical trials
5.2. Cumulative Impact of COVID-19
6. Prostate Cancer Diagnostics Market, by Test Type
6.1. Introduction
6.2. Confirmatory Tests
6.3.1. Biopsy
6.3.2. PCA3 Tests
6.3.3. Trans-rectal Ultrasound
6.3. Preliminary Tests
7. Prostate Cancer Diagnostics Market, by Age Group
7.1. Introduction
7.2. Age 55-75
7.3. Age <55
7.4. Age>75
8. Prostate Cancer Diagnostics Market, by End-User
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Hospital Associated Laboratories
8.4. Independent Diagnostic Laboratories
9. Americas Prostate Cancer Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Prostate Cancer Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Prostate Cancer Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Accuquik Test Kits
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. ACON Laboratories, Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Astellas Pharma Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. AstraZeneca PLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Bayer AG
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Beckman Coulter Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. BioMérieux SA
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Dendreon Pharmaceuticals LLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. DiaSorin S.p.A.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Eurolyser Diagnostica GmbH
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Exact Sciences Corp.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. F. Hoffmann-La Roche AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Fujirebio
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Hologic Inc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Humasis Co
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Ipsen SA
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Koninklijke Philips NV
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Life Length
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. MDxHealth
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Metamark Genetics, Inc
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Myriad Genetics, Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. OPKO Health, Inc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Prostatype Genomics
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Proteomedix AG
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. Sanofi S.A.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services
13.27. Siemens Healthineers AG
13.27.1. Business Overview
13.27.2. Key Executives
13.27.3. Product & Services
13.28. Telo Genomics Corp.
13.28.1. Business Overview
13.28.2. Key Executives
13.28.3. Product & Services
13.29. Tolmar Inc.
13.29.1. Business Overview
13.29.2. Key Executives
13.29.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing